MAPT and Dravet syndrome: Additionally, EVs displayed significant therapeutic effect on cellular phenotypes associated with degenerative changes in DS and were able to mitigate AD pathology by reducing Aβ levels in both the soluble and insoluble fractions, decreasing levels of p-tau concentrations and reducing markers of cell death in trisomic CS.